A Noninvasive Predictors of Significant Histological Activity in Chronic Liver Diseases: The Role of Matrix Metalloproteinases

Aim of investigation. To study the prognostic significance of clinical and laboratory markers of liver pathology, including components of the matrix metalloproteinase (MMP) system, to identify moderate/significant activity in chronic liver diseases (CLD). Materials and methods. 76 patients with CLD of viral or alcoholic etiology aged from 18 to 64 years were examined. Minimal (histological activity index — HAI 1-3 points), minor (HAI 4-8 points), moderate (HAI 9-12 points) and significant morphological activity (HAI more than 12 points) were detected in 19 (25.0 %), 34 (44.7 %), 14 (18.4 %) and 9 (11.9 %) of cases, respectively. Enzyme immunoassay was used to determine the blood levels of MMP-1, MMP-9, tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), and the of TIMP-1/MMP-1, TIMP-1/MMP-9 was calculated. Results. According to multivariate logistic regression data, moderate/significant histological activity of CLD was associated with γ-glutamyltranspeptidase (GGT) (odds ratio (OR) 1.016; 95 % confidence interval (CI) (1.006-1.024), p=0.001), international normalized ratio (INR) (OR 1.079; 95 % CI (1.028-1.132), p=0.002), and TIMP-1/MMP- 9 ratio (OR 0.554; 95 % CI (0.380-0.809), p=0.002). The combination of these parameters had sensitivity of 82.6 %, specificity of 92.5 % and accuracy of 89.5 % in detecting HAI of 9 or more points. Conclusion. The increased values of GGT and INR, as well as a reduced ratio of TIMP-1/MMP-9, are independent risk factors for moderate/significant histological activity in CLD, due to their participation in the processes of hepatic inflammation.

1. Moon A.M., Singal A.G., Tapper E.B. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18: 2650-2666. doi: 10.1016/j.cgh.2019.07.060

2. Devarbhavi H., Asrani S.K., Arab J.P. et al. Global burden of liver disease: 2023 update. J. Hepatol. 2023; 79 (2): 516-537. doi: 10.1016/j.jhep.2023.03.017

3. Jeng W., Papatheodoridis G., Lok A.S. F. Hepatitis B. Lancet. 2023; 401 (10381): 1039-1052. doi: 10.1016/s0140-6736(22)01468-4

4. Stockdale A.J., Kreuels B., Henrion M.Y. R. et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. 2020; 73: 523-532. doi: 10.1016/j.jhep.2020.04.008

5. Petagine L., Zariwala M.G., Patel V.B. Alcoholic liver disease: current insights into cellular mechanisms. World J. Biol. Chem. 2021; 12 (5): 87-103. doi: 10.4331/wjbc.v12.i5.87.

6. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J. Hepatol. 2021; 75 (3): 659-689. doi: 10.1016/j.jhep.2021.05.025

7. Pokorska-Śpiewak M., Kowalik-Mikołajewska B., Aniszewska M. et al. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest — comparison with histopathological assessment. Clin. Exp. Hepatol. 2017; 3 (4): 187-193. doi: 10.5114/ceh.2017.7107919

8. Bril F., McPhaul M.J., Caulfield M.P. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 dibetes mellitus. J. Investig. Med. 2019; 67: 303-311. doi: 10.1136/jim-2018-000864

9. Geervliet E., Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020; 9: 1212. doi: 10.3390/cells9051212

10. Chen J., Xu W., Chen Y. et al. Matrix metalloproteinase 9 facilitates hepatitis B virus replication through binding with type I interferon (IFN) receptor 1 to repress IFN/JAK/STAT signaling. J. Virol. 2017; 91 (8): e01824-16. doi: 10.1128/JVI.01824-16

11. Wang X., Maretti-Mira A.C., Wang L. et al. Liver-selective MMP- 9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regeneration. Hepatology. 2019; 69: 314-328. doi: 10.1002/hep.30169

12. Yagoda A.V., Koroy P.V., Dudov T.R. Matrix metalloproteinases and morphological features in chronic liver diseases. Experimental and Clinical Gastroenterology. 2023; 218 (10): 153-159. doi: 10.31146/1682-8658-ecg-218-10-153-159 [In Russian]

13. Behairy O.G., El-Bakry M.M., Mansour A.I. et al. Matrix metalloproteinase-1 as a non-invasive biomarker to assess liver fibrosis in children with chronic liver disease. Egypt. Liver J. 2021; 11: 80. doi: 10.1186/s43066-021-00148-x

14. Lam S., Singh R., Dillman J.R. et al. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatology Communications. 2020; 4 (11): 1680-1693. doi: 10.1002/hep4.1589

15. Zhan J., Wang J., Zhang Z. et al. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase. Virulence. 2023; 14 (1). 2268497. doi: 10.1080/21505594.2023.2268497

16. Chen S., Huang H. Clinical non-invasive model to predict liver inflammation in chronic hepatitis B with alanine aminotransferase ≤ 2 upper limit of normal. Front. Med. 2021; 8: 661725. doi: 10.3389/fmed.2021.66172529

17. Jiang S., Wang J., Zhang Z. et al. Development and validation of a nomogram to predict significant liver inflammation in patients with chronic hepatitis B. Infect. Drug Resist. 2023; 16: 5065-5075. doi: 10.2147/IDR.S417007

18. Li X., Xing Y., Zhou D. et al. A non-invasive model for predicting liver inflammation in chronic hepatitis B patients with normal serum alanine aminotransferase levels. Front. Med. 2021; 8: 688091. doi: 10.3389/fmed.2021.688091

19. Xu W.S., Qiu X.M., Ou Q.S. et al. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine. 2015; 94 (10): e612. doi: 10.1097/MD.0000000000000612

20. Wang H., Xu H., Qu L. et al. Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients. Eur. J. Gastroenterol. Hepatol. 2016; 28: 997-1002. doi: 10.1097/MEG.0000000000000662

21. Yao M., Wang L., Wang J. et al. Diagnostic value of serum Golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis. Dis. Markers. 2022; 2022: 4253566. doi: 10.1155/2022/4253566

22. Yao K., Wang J., Wang L. et al. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J. Med. Virol. 2022; 94 (2): 659-666. doi: 10.1002/jmv.27327

23. Liu J., Wang J., Yan X. et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol. Commun. 2022; 6 (4): 855- 866. doi: 10.1002/hep4.1859

24. Mussbacher M., Brunnthaler L., Panhuber A. et al. Till death do us part — the multifaceted role of platelets in liver diseases. Int. J. Mol. Sci. 2021; 22: 3113. doi: 10.3390/ijms22063113

25. Negrin L.L., Carlin G.L., Ristl R. et al. Serum levels of matrix metalloproteinases 1, 2, and 7, and their tissue inhibitors 1, 2, 3, and 4 in polytraumatized patients: time trajectories, correlations, and their ability to predict mortality. PLoS One. 2024; 19 (3): e0300258. doi: 10.1371/journal.pone.0300258

26. Shan L., Wang F., Zhai D J. et al. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. Biomed. Pharmacother. 2023; 161: 114472. doi: 10.1016/j.biopha.2023.114472

27. Latronico T., Mascia C., Pati I. et al. Liver fibrosis in HCV monoinfected and HIV/HCV coinfected patients: dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and effect of HCV protease inhibitors. Int. J. Mol. Sci. 2016; 17: 455. doi: 10.3390/ijms17040455

28. Tsomidis I., Notas G., Xidakis C. et al. Enzymes of fibrosis in chronic liver disease. Biomedicines. 2022; 10 (12): 3179. doi: 10.3390/biomedicines10123179

29. Ando W., Yokomori H., Tsutsui N. et al. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin. Mol. Hepatol. 2018; 24 (1): 61-76. doi: 10.3350/cmh.2017.0030

30. Martinez-Castillo M., Hernandez-Barragan A., Flores-Vasconcelos I. et al. Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients. World J. Hepatol. 2021; 13 (2): 218-232. doi: 10.4254/wjh.v13.i2.218

31. Zdanowicz K., Kowalczuk-Kryston M., Olanski W. et al. Increase in serum MMP-9 and TIMP-1 concentrations during alcohol intoxication in adolescents — a preliminary study. Biomolecules. 2022; 12: 710. doi: 10.3390/biom12050710

32. Li Y., Liu H., Xu L. Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation. Exp. Ther. Med. 2018; 16: 4136-4140. doi: 10.3892/etm.2018.6673

33. Yu D., Li Y., Xu Y. et al. Dysregulated matrix metalloproteinases and tissue inhibitors of metalloproteinase in residual splenic tissue after subtotal splenectomy due to portal hypertension. Int. J. Clin. Exp. Pathol. 2017; 10 (2): 1273-1282.

34. Sufleţel R.T., Melincovici C.S., Gheban B.A. et al. Hepatic stellate cells — from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom. J. Morphol. Embryol. 2020; 61 (3): 615-642. doi: 10.47162/RJME.61.3.01

35. Andrade T.G., Xavier L.C. D., Souza F.F. et al. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease — a survey in a university hospital in Brazil. Arch. Endocrinol. Metab. 2022; 66 (6): 823-830. doi: 10.20945/2359-3997000000514

36. Kravchenko Yu.A., Koroy P.V. «Inflammatory index» and histological features in nonalcoholic fatty liver disease. Medical News of North Caucasus. 2023; 18 (4): 409-411. doi: 10.14300/mnnc.2023.18097 [In Russian]

37. Yagoda A.V., Koroy P.V., Slyadnev S.A. Positive correlation of the level of molecules of superfamily immunoglobulins ICAM-1, VCAM-1 and PECAM-1 with the index of fibrosis in nonalcoholic fatty liver disease. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017; 138 (2): 45-51. [In Russian]